Boston Scientific Corp. (NYSE:BSX) is one of the 10 oversold stocks offering high upside.
On June 12, Matt O’Brien from Piper Sandler reduced the target price on Boston Scientific Corporation (NYSE:BSX) from $90 to $65, resulting in an adjusted upside potential of close to 45% at the current level
RAJ CREATIONZS / The analyst retained an Overweight rating on the stock, observing that the shares have significantly declined in light of a slowdown in some key indicators, and the route to reaching the company’s longstanding revenue growth target of 10% or more. Earlier on June 3, Marie Thibault from BTIG also reduced the price target on Boston Scientific Corporation (NYSE:BSX) from $80 to $65, and upheld her Buy rating on the stock. This update has been attributed to the management’s expectations of slower growth for the company’s Watchman line over the next two quarters.
Thibault also noted that due to low current visibility, she expects flat sales for the second and third quarters. Looking ahead, the analyst projects a small quarter-over-quarter increase during the fourth quarter, followed by a steady and gradual recovery across 2027. Boston Scientific Corp. (NYSE:BSX) specializes in medical devices for interventional specialties such as cardiovascular, endo-surgery, and neuro-modulation.